Publisher
Springer Science and Business Media LLC
Subject
Law,Sociology and Political Science,Anthropology
Reference80 articles.
1. Agenzia Italiana del Farmaco (AIFA). (2017). Criteri per la classificazione dei farmaci innovativi e dei farmaci oncologici innovati. Determina AIFA n. 1535/2017.
www.aifa.gov.it/content/criteri-la-classificazione-dei-farmaci-innovativi-e-dei-farmaci-oncologici-innovativi-180920
. Accessed February 23, 2019.
2. Angelis, A., Lange, A., & Kanvos, P. (2018). Using health technology assessment to assess the value of new medicines: Results of a systematic review and expert consultation across eight European countries. The European Journal of Health Economics,
19(1), 123–152.
3. Aronson, J. K., Ferner, R. E., & Hughes, D. A. (2012). Defining rewardable innovation in drug therapy. Nature Reviews Drug Discovery,
11(4), 253–254.
4. Brock, D. W. (2003). Separate spheres and indirect benefits. Cost Effectiveness and Resource Allocation,
1, 4.
5. Bryan, S., Lee, H., & Mitton, C. (2013). ‘Innovation’ in health care coverage decisions: All talk and no substance? Journal of Health Services Research & Policy,
18(1), 57–60.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献